*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
The peptide used to generate this antibody is available for purchase (GTX89268-PEP).
This antibody is expected to recognise both reported isoforms (NP_000542.1 and NP_937799.1).
Tris saline pH7.3, 0.02% sodium azide, 0.5% BSA.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Peptide with sequence C-RSLVKPENYRRLD, from the internal region of the protein sequence according to NP_000542.1; NP_937799.1.
Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
von Hippel-Lindau tumor suppressor , HRCA1 , RCA1 , VHL1 , pVHL
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]